Cell Therapy Market Report and Forecast 2025-2034
Description
The global cell therapy market size was valued at USD 4.18 Billion in 2024. The market size is projected to grow at a compound annual growth rate (CAGR) of 11.20% during the forecast period from 2025 to 2034, with market size values likely reaching USD 12.08 Billion by 2034. Advances in therapeutic development, and the emphasis of biotechnology companies to promote innovative cell therapies, regenerative medicine, are amongst the key trends in the healthcare industry. The market growth is also driven by the rising development around new cell types.
Cell Therapy Market Trends
Recent advances in cell therapy clinical studies have paved the way for innovative treatment options. Improvements in cell therapy manufacturing have streamlined production processes. While the supply chain has been strengthened by advancing cell banking facilities and optimized cell storage. Rigorous cell characterization ensures the highest standards in cell-based therapeutics. These developments are transforming research and clinical applications. Innovations continue to drive the integration of quality controls and scalable production methods. Overall, the emphasis on comprehensive cell therapy clinical studies and robust cell therapy manufacturing is fostering growth and improved outcomes in cell-based therapeutics.
Ongoing clinical trials support emerging innovations in the field, with backing from government funding agencies and EU grants. Advances in personalized therapy manufacturing are accelerating development. By the end of 2023, 76 cell and gene therapies were launched globally. This was more than double the number seen in 2013, demonstrating rapid market expansion.
Personalized medicine is experiencing a paradigm shift with the use of genetically modified cells. Customized treatments based on an individual’s genetic makeup are enhancing efficacy and safety, marking a transformative change in therapeutic strategies.
Stem cell therapy is being utilized to treat autoimmune disorders and metabolic disorders. The use of induced pluripotent stem cells (iPSC) has advanced treatments for insulin-dependent diabetes. Automation in stem cell processing, along with improvements in cord blood processing and cord blood storage, has enhanced efficiency and reliability. Newborn stem cells and induced pluripotent stem cells (iPSCs) are now key to advancing regenerative medicine. These innovations are expanding treatment options and elevating the standard of care, reinforcing the critical role of stem cell therapy in modern healthcare.
Cell Therapy Market Concentration & Characteristics
The cell therapy market demonstrates a high degree of innovation, driven by groundbreaking research and advanced biotechnological applications. Robust scientific progress and novel therapeutic approaches continue to expand the scope of potential treatments, transforming patient outcomes worldwide.
Recent merger and acquisition activities have reshaped the competitive landscape within the cell therapy market. Strategic alliances and corporate consolidations drive resource optimization, enhance research capabilities, and foster accelerated innovation to address complex clinical challenges.
Regulatory frameworks significantly influence the cell therapy market, ensuring product safety and efficacy. Strict guidelines promote transparency and compliance while potentially delaying market entry for innovative therapies.
Product expansion and regional expansion are driving factors in the evolving cell therapy market. Companies are diversifying product portfolios while expanding into emerging markets to access broader patient populations and capitalize on regional growth opportunities.
Cell Type Insights
Based on cell type, the cell therapy market is divided into T cells, stem cells, and others. Among these, stem cells are expected to hold the largest market share due to their versatility in regenerative medicine and their potential to treat a wide range of diseases. Stem cells’ ability to differentiate into various cell types is crucial in advancing cell therapy for conditions like cancer, cardiovascular diseases, and neurological disorders. Their regenerative capabilities make them key players in the market, particularly for chronic and debilitating conditions.
The T cells segment is anticipated to grow significantly, driven by their essential role in immunotherapy, particularly in cancer treatment. Engineered T cells, such as CAR-T cells, have shown remarkable results in treating blood cancers, further boosting their market presence. The other segments include natural killer (NK) cells, dendritic cells, and macrophages, which are increasingly being explored for their potential in immune modulation and cancer therapies, supporting overall market growth.
Application Insights
The cell therapy market is segmented by application into cancer, cardiovascular diseases, orthopedic disorders, autoimmune diseases, and others. The cancer segment is expected to dominate the market share due to the rising incidence of cancer globally and increasing demand for innovative treatment solutions. The advancement of cell-based cancer therapies, such as CAR-T cell therapy, has significantly contributed to the growth of this segment, addressing unmet medical needs and offering targeted treatments.
The expanding research in regenerative medicine and its applications across various therapeutic areas drive this progress. Cardiovascular diseases and orthopedic disorders benefit from the development of effective solutions for chronic conditions, while autoimmune diseases see increased adoption of cell therapies for managing complex immune responses. These factors collectively enhance the diversity and growth prospects of the cell therapy market.
Cell Therapy Market Regional Insights
The global cell therapy market is experiencing rapid and widespread growth across all major regions, including North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America, particularly the United States, continues to lead the sector, with 694 cell and gene therapies (CGTs) in development as of February 2024 . These therapies are regarded as revolutionary in treating chronic diseases, offering more effective solutions that often require fewer doses than traditional treatments. The United States has already approved 14 CGTs, with more than 70% of these approvals granted in the past five years. Although there are areas for improvement, such as cost management, regulatory processes, and patient access, the future of cell and gene therapies remains highly promising. These therapies are expected to transform healthcare by providing personalized, regenerative treatments for various conditions, including genetic disorders, cancers, and chronic diseases.
In Europe, the market for cell therapy is also advancing significantly, driven by innovative therapies such as Chimeric Antigen Receptor (CAR) T-cell therapy. The increasing adoption of CAR-T therapies across European countries, supported by robust research and development efforts, has spurred market growth. Furthermore, regulatory enhancements and healthcare infrastructure upgrades have improved accessibility and expanded the application of these therapies throughout the region.
In the Asia-Pacific region, India’s introduction of its first homegrown CAR-T cell therapy for cancer in April 2024 highlights the growing capabilities in cell therapy within the region. Developed through collaboration between the Indian Institute of Technology, Bombay, Tata Memorial Hospital, and ImmunoACT, this achievement showcases the region’s expanding potential and innovation in the field of advanced therapies.
Cell Therapy Market Key Companies & Market Share Insights
The market is driven by key companies leveraging collaborations, partnerships, and technological advancements to enhance therapeutic solutions. These companies are pivotal in shaping market growth through innovation and strategic initiatives. Some major players include:
Thermo Fisher Scientific Inc.
Founded in 1956 and located in Waltham, Massachusetts, Thermo Fisher Scientific is a leader in lab instruments and reagents. In the cell therapy field, the company supports manufacturing through innovative solutions. In February 2024 , Thermo Fisher teamed up with Multiply Labs to automate production. The partnership integrates robotics and advanced equipment, improving scalability, cutting costs, and speeding up processes.
Merck KGaA
Merck KGaA, established in 1668 and headquartered in Darmstadt, Germany, excels in science and technology. In the cell therapy sector, the company focuses on viral vector manufacturing. In May 2024, Merck acquired Mirus Bio for USD 600 million, boosting its viral vector production capabilities and reinforcing its commitment to cell and gene therapies.
Danaher Corporation
Danaher Corporation, founded in 1969, is leading in life sciences and diagnostics. The company’s expertise spans cell culture, gene editing, and biomanufacturing. In January 2024, it partnered with the Innovative Genomics Institute to scale CRISPR-based treatments, enhancing gene-editing technologies in cell and gene therapy.
Novartis AG
Novartis AG, based in Basel, Switzerland, was founded in 1996. Known for its leadership in CAR-T therapies. It advanced this field further in November 2024 through a partnership with Vyriad. By combining Vyriad’s lentiviral vector technology with Novartis's expertise, the collaboration aims to expand treatment possibilities in CAR-T therapies.
Other key players in the market are Becton, Dickinson and Company, Terumo BCT, Inc., Sartorius AG, Corning Incorporated and Lonza.
Recent Developments
Cell Therapy Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Offerings Outlook
Cell Therapy Market Trends
Recent advances in cell therapy clinical studies have paved the way for innovative treatment options. Improvements in cell therapy manufacturing have streamlined production processes. While the supply chain has been strengthened by advancing cell banking facilities and optimized cell storage. Rigorous cell characterization ensures the highest standards in cell-based therapeutics. These developments are transforming research and clinical applications. Innovations continue to drive the integration of quality controls and scalable production methods. Overall, the emphasis on comprehensive cell therapy clinical studies and robust cell therapy manufacturing is fostering growth and improved outcomes in cell-based therapeutics.
Ongoing clinical trials support emerging innovations in the field, with backing from government funding agencies and EU grants. Advances in personalized therapy manufacturing are accelerating development. By the end of 2023, 76 cell and gene therapies were launched globally. This was more than double the number seen in 2013, demonstrating rapid market expansion.
Personalized medicine is experiencing a paradigm shift with the use of genetically modified cells. Customized treatments based on an individual’s genetic makeup are enhancing efficacy and safety, marking a transformative change in therapeutic strategies.
Stem cell therapy is being utilized to treat autoimmune disorders and metabolic disorders. The use of induced pluripotent stem cells (iPSC) has advanced treatments for insulin-dependent diabetes. Automation in stem cell processing, along with improvements in cord blood processing and cord blood storage, has enhanced efficiency and reliability. Newborn stem cells and induced pluripotent stem cells (iPSCs) are now key to advancing regenerative medicine. These innovations are expanding treatment options and elevating the standard of care, reinforcing the critical role of stem cell therapy in modern healthcare.
Cell Therapy Market Concentration & Characteristics
The cell therapy market demonstrates a high degree of innovation, driven by groundbreaking research and advanced biotechnological applications. Robust scientific progress and novel therapeutic approaches continue to expand the scope of potential treatments, transforming patient outcomes worldwide.
Recent merger and acquisition activities have reshaped the competitive landscape within the cell therapy market. Strategic alliances and corporate consolidations drive resource optimization, enhance research capabilities, and foster accelerated innovation to address complex clinical challenges.
Regulatory frameworks significantly influence the cell therapy market, ensuring product safety and efficacy. Strict guidelines promote transparency and compliance while potentially delaying market entry for innovative therapies.
Product expansion and regional expansion are driving factors in the evolving cell therapy market. Companies are diversifying product portfolios while expanding into emerging markets to access broader patient populations and capitalize on regional growth opportunities.
Cell Type Insights
Based on cell type, the cell therapy market is divided into T cells, stem cells, and others. Among these, stem cells are expected to hold the largest market share due to their versatility in regenerative medicine and their potential to treat a wide range of diseases. Stem cells’ ability to differentiate into various cell types is crucial in advancing cell therapy for conditions like cancer, cardiovascular diseases, and neurological disorders. Their regenerative capabilities make them key players in the market, particularly for chronic and debilitating conditions.
The T cells segment is anticipated to grow significantly, driven by their essential role in immunotherapy, particularly in cancer treatment. Engineered T cells, such as CAR-T cells, have shown remarkable results in treating blood cancers, further boosting their market presence. The other segments include natural killer (NK) cells, dendritic cells, and macrophages, which are increasingly being explored for their potential in immune modulation and cancer therapies, supporting overall market growth.
Application Insights
The cell therapy market is segmented by application into cancer, cardiovascular diseases, orthopedic disorders, autoimmune diseases, and others. The cancer segment is expected to dominate the market share due to the rising incidence of cancer globally and increasing demand for innovative treatment solutions. The advancement of cell-based cancer therapies, such as CAR-T cell therapy, has significantly contributed to the growth of this segment, addressing unmet medical needs and offering targeted treatments.
The expanding research in regenerative medicine and its applications across various therapeutic areas drive this progress. Cardiovascular diseases and orthopedic disorders benefit from the development of effective solutions for chronic conditions, while autoimmune diseases see increased adoption of cell therapies for managing complex immune responses. These factors collectively enhance the diversity and growth prospects of the cell therapy market.
Cell Therapy Market Regional Insights
The global cell therapy market is experiencing rapid and widespread growth across all major regions, including North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America, particularly the United States, continues to lead the sector, with 694 cell and gene therapies (CGTs) in development as of February 2024 . These therapies are regarded as revolutionary in treating chronic diseases, offering more effective solutions that often require fewer doses than traditional treatments. The United States has already approved 14 CGTs, with more than 70% of these approvals granted in the past five years. Although there are areas for improvement, such as cost management, regulatory processes, and patient access, the future of cell and gene therapies remains highly promising. These therapies are expected to transform healthcare by providing personalized, regenerative treatments for various conditions, including genetic disorders, cancers, and chronic diseases.
In Europe, the market for cell therapy is also advancing significantly, driven by innovative therapies such as Chimeric Antigen Receptor (CAR) T-cell therapy. The increasing adoption of CAR-T therapies across European countries, supported by robust research and development efforts, has spurred market growth. Furthermore, regulatory enhancements and healthcare infrastructure upgrades have improved accessibility and expanded the application of these therapies throughout the region.
In the Asia-Pacific region, India’s introduction of its first homegrown CAR-T cell therapy for cancer in April 2024 highlights the growing capabilities in cell therapy within the region. Developed through collaboration between the Indian Institute of Technology, Bombay, Tata Memorial Hospital, and ImmunoACT, this achievement showcases the region’s expanding potential and innovation in the field of advanced therapies.
Cell Therapy Market Key Companies & Market Share Insights
The market is driven by key companies leveraging collaborations, partnerships, and technological advancements to enhance therapeutic solutions. These companies are pivotal in shaping market growth through innovation and strategic initiatives. Some major players include:
Thermo Fisher Scientific Inc.
Founded in 1956 and located in Waltham, Massachusetts, Thermo Fisher Scientific is a leader in lab instruments and reagents. In the cell therapy field, the company supports manufacturing through innovative solutions. In February 2024 , Thermo Fisher teamed up with Multiply Labs to automate production. The partnership integrates robotics and advanced equipment, improving scalability, cutting costs, and speeding up processes.
Merck KGaA
Merck KGaA, established in 1668 and headquartered in Darmstadt, Germany, excels in science and technology. In the cell therapy sector, the company focuses on viral vector manufacturing. In May 2024, Merck acquired Mirus Bio for USD 600 million, boosting its viral vector production capabilities and reinforcing its commitment to cell and gene therapies.
Danaher Corporation
Danaher Corporation, founded in 1969, is leading in life sciences and diagnostics. The company’s expertise spans cell culture, gene editing, and biomanufacturing. In January 2024, it partnered with the Innovative Genomics Institute to scale CRISPR-based treatments, enhancing gene-editing technologies in cell and gene therapy.
Novartis AG
Novartis AG, based in Basel, Switzerland, was founded in 1996. Known for its leadership in CAR-T therapies. It advanced this field further in November 2024 through a partnership with Vyriad. By combining Vyriad’s lentiviral vector technology with Novartis's expertise, the collaboration aims to expand treatment possibilities in CAR-T therapies.
Other key players in the market are Becton, Dickinson and Company, Terumo BCT, Inc., Sartorius AG, Corning Incorporated and Lonza.
Recent Developments
- In March 2025, Anova Therapeutics’ Phase I/II gene therapy, DB107, enrolled its first patients for treating high-grade gliomas. The therapy aims to reduce toxicity while enhancing immune response and is supported by a California grant. The therapy works by combining a retroviral vector and an oral prodrug. The vector selectively infects and modifies cancer cells, while the drug transforms into a chemotherapeutic agent within the tumor.
- In February 2025, Cellistic launched Allo Chassis, ready-to-use, immune-cloaked iPSC cell lines derived from CD34+ and CD4+ T-cells. These cGMP-compliant cell lines streamline cell therapy development, reducing costs and accelerating timelines.
- In January 2025, Baptist MD Anderson Cancer Center launched a stem cell transplantation and cellular therapy program, introducing CAR T-cell therapy for blood cancers and stem cell transplants in late 2025.
- In December 2024, U.S. Food and Drug Administration approved Ryoncil (remestemcel-L-rknd), an allogeneic mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease (SR-aGVHD).
- In November 2024, MD Anderson Cancer Center launched the Institute for Cell Therapy Discovery & Innovation to advance cell therapies for cancer, autoimmune diseases, and infections, supported by over USD 80 million.
- In November 2024, Roche entered into a definitive agreement to acquire Poseida Therapeutics for approximately USD 1.5 billion, enhancing its cell therapy portfolio, particularly in oncology, immunology, and neurology.
- In September 2024, GC Therapeutics (GCTx) launched with USD 75 million in capital. Its TFome platform integrates synthetic biology and gene editing to enhance cell therapy scalability and accessibility across multiple diseases.
- In July 2024, Bioserve India launched advanced stem cell products in India, supporting innovation in regenerative medicine, drug development, and therapeutic discovery, enhancing stem cell research and therapy advancements.
Cell Therapy Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Offerings Outlook
- Media, Sera, and Reagents
- Cell Therapy Equipment
- Systems and Software
- Cell Culture Vessels
- Cell Engineering Products
- Others
- Cell Processing
- Cell Preservation
- Process Monitoring & Quality Control
- Cell Handling
- Cell Distribution
- T Cells
- Stem Cells
- Others
- Cancer
- Cardiovascular Diseases
- Orthopedic Disorders
- Autoimmune Diseases
- Others
- Pharmaceutical & Biotechnology Companies
- CROs and CMOs
- Research Institutes
- Cell Banks
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Cell Therapy Market Overview
- 3.1 Global Cell Therapy Market Historical Value (2018-2024)
- 3.2 Global Cell Therapy Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Cell Therapy Market Landscape*
- 5.1 Global Cell Therapy Market: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Cell Therapy Market: Product Landscape
- 5.2.1 Analysis by Offerings
- 5.2.2 Analysis by Process
- 5.2.3 Analysis by Cell Type
- 5.2.4 Analysis by Application
- 6 Global Cell Therapy Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Cell Therapy Market Segmentation (218-2034)
- 7.1 Global Cell Therapy Market (2018-2034) by Offerings
- 7.1.1 Market Overview
- 7.1.2 Media, Sera and Reagents
- 7.1.3 Cell Therapy Equipment
- 7.1.4 Systems & Software
- 7.1.5 Cell Culture Vessels
- 7.1.6 Cell Engineering Products
- 7.1.7 Others
- 7.2 Global Cell Therapy Market (2018-2034) by Process
- 7.2.1 Market Overview
- 7.2.2 Cell Processing
- 7.2.3 Cell Preservation
- 7.2.4 Process Monitoring & Quality Control
- 7.2.5 Cell Handling
- 7.2.6 Cell Distribution
- 7.3 Global Cell Therapy Market (2018-2034) by Cell Type
- 7.3.1 Market Overview
- 7.3.2 T Cells
- 7.3.3 Stem Cells
- 7.3.4 Others
- 7.4 Global Cell Therapy Market (2018-2034) by Application
- 7.4.1 Market Overview
- 7.4.2 Cancer
- 7.4.3 Cardiovascular Diseases
- 7.4.4 Orthopedic Disorders
- 7.4.5 Autoimmune Diseases
- 7.4.6 Others
- 7.5 Global Cell Therapy Market (2018-2034) by End User
- 7.5.1 Market Overview
- 7.5.2 Pharmaceutical & Biotechnology Companies
- 7.5.3 CROs and CMOs
- 7.5.4 Research Institutes
- 7.5.5 Cell Banks
- 7.5.6 Others
- 7.6 Global Cell Therapy Market (2018-2034) by Region
- 7.6.1 Market Overview
- 7.6.2 North America
- 7.6.3 Europe
- 7.6.4 Asia Pacific
- 7.6.5 Latin America
- 7.6.6 Middle East and Africa
- 8 North America Cell Therapy Market (218-2034)
- 8.1 North America Cell Therapy Market (2018-2034) by Offerings
- 8.1.1 Market Overview
- 8.1.2 Media, Sera and Reagents
- 8.1.3 Cell Therapy Equipment
- 8.1.4 Systems & Software
- 8.1.5 Cell Culture Vessels
- 8.1.6 Cell Engineering Products
- 8.1.7 Others
- 8.2 North America Cell Therapy Market (2018-2034) by Process
- 8.2.1 Market Overview
- 8.2.2 Cell Processing
- 8.2.3 Cell Preservation
- 8.2.4 Process Monitoring & Quality Control
- 8.2.5 Cell Handling
- 8.2.6 Cell Distribution
- 8.3 North America Cell Therapy Market (2018-2034) by Cell Type
- 8.3.1 Market Overview
- 8.3.2 T Cells
- 8.3.3 Stem Cells
- 8.3.4 Others
- 8.4 North America Cell Therapy Market (2018-2034) by Application
- 8.4.1 Market Overview
- 8.4.2 Cancer
- 8.4.3 Cardiovascular Diseases
- 8.4.4 Orthopedic Disorders
- 8.4.5 Autoimmune Diseases
- 8.4.6 Others
- 8.5 North America Cell Therapy Market (2018-2034) by End User
- 8.5.1 Market Overview
- 8.5.2 Pharmaceutical & Biotechnology Companies
- 8.5.3 CROs and CMOs
- 8.5.4 Research Institutes
- 8.5.5 Cell Banks
- 8.5.6 Others
- 8.6 North America Cell Therapy Market (2018-2034) by Country
- 8.6.1 United States of America
- 8.6.1.1 United States of America Cell Therapy Market (2018-2034) by Offerings
- 8.6.2 Canada
- 8.6.2.1 Canada Cell Therapy Market (2018-2034) by Offerings
- 9 Europe Cell Therapy Market (218-2034)
- 9.1 Europe Cell Therapy Market (2018-2034) by Offerings
- 9.1.1 Market Overview
- 9.1.2 Media, Sera and Reagents
- 9.1.3 Cell Therapy Equipment
- 9.1.4 Systems & Software
- 9.1.5 Cell Culture Vessels
- 9.1.6 Cell Engineering Products
- 9.1.7 Others
- 9.2 Europe Cell Therapy Market (2018-2034) by Process
- 9.2.1 Market Overview
- 9.2.2 Cell Processing
- 9.2.3 Cell Preservation
- 9.2.4 Process Monitoring & Quality Control
- 9.2.5 Cell Handling
- 9.2.6 Cell Distribution
- 9.3 Europe Cell Therapy Market (2018-2034) by Cell Type
- 9.3.1 Market Overview
- 9.3.2 T Cells
- 9.3.3 Stem Cells
- 9.3.4 Others
- 9.4 Europe Cell Therapy Market (2018-2034) by Application
- 9.4.1 Market Overview
- 9.4.2 Cancer
- 9.4.3 Cardiovascular Diseases
- 9.4.4 Orthopedic Disorders
- 9.4.5 Autoimmune Diseases
- 9.4.6 Others
- 9.5 Europe Cell Therapy Market (2018-2034) by End User
- 9.5.1 Market Overview
- 9.5.2 Pharmaceutical & Biotechnology Companies
- 9.5.3 CROs and CMOs
- 9.5.4 Research Institutes
- 9.5.5 Cell Banks
- 9.5.6 Others
- 9.6 Europe Cell Therapy Market (2018-2034) by Country
- 9.6.1 United Kingdom
- 9.6.1.1 United Kingdom Cell Therapy Market (2018-2034) by Offerings
- 9.6.2 Germany
- 9.6.2.1 Germany Cell Therapy Market (2018-2034) by Offerings
- 9.6.3 France
- 9.6.3.1 France Cell Therapy Market (2018-2034) by Offerings
- 9.6.4 Italy
- 9.6.4.1 Italy Cell Therapy Market (2018-2034) by Offerings
- 9.6.5 Others
- 10 Asia Pacific Cell Therapy Market (218-2034)
- 10.1 Asia Pacific Cell Therapy Market (2018-2034) by Offerings
- 10.1.1 Market Overview
- 10.1.2 Media, Sera and Reagents
- 10.1.3 Cell Therapy Equipment
- 10.1.4 Systems & Software
- 10.1.5 Cell Culture Vessels
- 10.1.6 Cell Engineering Products
- 10.1.7 Others
- 10.2 Asia Pacific Cell Therapy Market (2018-2034) by Process
- 10.2.1 Market Overview
- 10.2.2 Cell Processing
- 10.2.3 Cell Preservation
- 10.2.4 Process Monitoring & Quality Control
- 10.2.5 Cell Handling
- 10.2.6 Cell Distribution
- 10.3 Asia Pacific Cell Therapy Market (2018-2034) by Cell Type
- 10.3.1 Market Overview
- 10.3.2 T Cells
- 10.3.3 Stem Cells
- 10.3.4 Others
- 10.4 Asia Pacific Cell Therapy Market (2018-2034) by Application
- 10.4.1 Market Overview
- 10.4.2 Cancer
- 10.4.3 Cardiovascular Diseases
- 10.4.4 Orthopedic Disorders
- 10.4.5 Autoimmune Diseases
- 10.4.6 Others
- 10.5 Asia Pacific Cell Therapy Market (2018-2034) by End User
- 10.5.1 Market Overview
- 10.5.2 Pharmaceutical & Biotechnology Companies
- 10.5.3 CROs and CMOs
- 10.5.4 Research Institutes
- 10.5.5 Cell Banks
- 10.5.6 Others
- 10.6 Asia Pacific Cell Therapy Market (2018-2034) by Country
- 10.6.1 China
- 10.6.1.1 China Cell Therapy Market (2018-2034) by Offerings
- 10.6.2 Japan
- 10.6.2.1 Japan Cell Therapy Market (2018-2034) by Offerings
- 10.6.3 India
- 10.6.3.1 India Cell Therapy Market (2018-2034) by Offerings
- 10.6.4 ASEAN
- 10.6.4.1 ASEAN Cell Therapy Market (2018-2034) by Offerings
- 10.6.5 Australia
- 10.6.5.1 Australia Cell Therapy Market (2018-2034) by Offerings
- 10.6.6 Others
- 11 Latin America Cell Therapy Market (218-2034)
- 11.1 Latin America Cell Therapy Market (2018-2034) by Offerings
- 11.1.1 Market Overview
- 11.1.2 Media, Sera and Reagents
- 11.1.3 Cell Therapy Equipment
- 11.1.4 Systems & Software
- 11.1.5 Cell Culture Vessels
- 11.1.6 Cell Engineering Products
- 11.1.7 Others
- 11.2 Latin America Cell Therapy Market (2018-2034) by Process
- 11.2.1 Market Overview
- 11.2.2 Cell Processing
- 11.2.3 Cell Preservation
- 11.2.4 Process Monitoring & Quality Control
- 11.2.5 Cell Handling
- 11.2.6 Cell Distribution
- 11.3 Latin America Cell Therapy Market (2018-2034) by Cell Type
- 11.3.1 Market Overview
- 11.3.2 T Cells
- 11.3.3 Stem Cells
- 11.3.4 Others
- 11.4 Latin America Cell Therapy Market (2018-2034) by Application
- 11.4.1 Market Overview
- 11.4.2 Cancer
- 11.4.3 Cardiovascular Diseases
- 11.4.4 Orthopedic Disorders
- 11.4.5 Autoimmune Diseases
- 11.4.6 Others
- 11.5 Latin America Cell Therapy Market (2018-2034) by End User
- 11.5.1 Market Overview
- 11.5.2 Pharmaceutical & Biotechnology Companies
- 11.5.3 CROs and CMOs
- 11.5.4 Research Institutes
- 11.5.5 Cell Banks
- 11.5.6 Others
- 11.6 Latin America Cell Therapy Market (2018-2034) by Country
- 11.6.1 Brazil
- 11.6.1.1 Brazil Cell Therapy Market (2018-2034) by Offerings
- 11.6.2 Argentina
- 11.6.2.1 Argentina Cell Therapy Market (2018-2034) by Offerings
- 11.6.3 Mexico
- 11.6.3.1 Mexico Cell Therapy Market (2018-2034) by Offerings
- 11.6.4 Others
- 12 Middle East and Africa Cell Therapy Market (218-2034)
- 12.1 Middle East and Africa Cell Therapy Market (2018-2034) by Offerings
- 12.1.1 Market Overview
- 12.1.2 Media, Sera and Reagents
- 12.1.3 Cell Therapy Equipment
- 12.1.4 Systems & Software
- 12.1.5 Cell Culture Vessels
- 12.1.6 Cell Engineering Products
- 12.1.7 Others
- 12.2 Middle East and Africa Cell Therapy Market (2018-2034) by Process
- 12.2.1 Market Overview
- 12.2.2 Cell Processing
- 12.2.3 Cell Preservation
- 12.2.4 Process Monitoring & Quality Control
- 12.2.5 Cell Handling
- 12.2.6 Cell Distribution
- 12.3 Middle East and Africa Cell Therapy Market (2018-2034) by Cell Type
- 12.3.1 Market Overview
- 12.3.2 T Cells
- 12.3.3 Stem Cells
- 12.3.4 Others
- 12.4 Middle East and Africa Cell Therapy Market (2018-2034) by Application
- 12.4.1 Market Overview
- 12.4.2 Cancer
- 12.4.3 Cardiovascular Diseases
- 12.4.4 Orthopedic Disorders
- 12.4.5 Autoimmune Diseases
- 12.4.6 Others
- 12.5 Middle East and Africa Cell Therapy Market (2018-2034) by End User
- 12.5.1 Market Overview
- 12.5.2 Pharmaceutical & Biotechnology Companies
- 12.5.3 CROs and CMOs
- 12.5.4 Research Institutes
- 12.5.5 Cell Banks
- 12.5.6 Others
- 12.6 Middle East and Africa Cell Therapy Market (2018-2034) by Country
- 12.6.1 Saudi Arabia
- 12.6.1.1 Saudi Arabia Cell Therapy Market (2018-2034) by Offerings
- 12.6.2 United Arab Emirates
- 12.6.2.1 United Arab Emirates Cell Therapy Market (2018-2034) by Offerings
- 12.6.3 Nigeria
- 12.6.3.1 Nigeria Cell Therapy Market (2018-2034) by Offerings
- 12.6.4 South Africa
- 12.6.4.1 South Africa Cell Therapy Market (2018-2034) by Offerings
- 12.6.5 Others
- 13 Regulatory Framework
- 13.1 Regulatory Overview
- 13.2 US FDA
- 13.3 EU EMA
- 13.4 INDIA CDSCO
- 13.5 JAPAN PMDA
- 13.6 Others
- 14 Patent Analysis
- 14.1 Analysis by Type of Patent
- 14.2 Analysis by Publication Year
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Patent Age
- 14.5 Analysis by CPC Analysis
- 14.6 Analysis by Patent Valuation
- 14.7 Analysis by Key Players
- 15 Funding and Investment Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Type of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Strategic Initiatives
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Initiatives
- 16.3 Analysis by Joint Ventures
- 16.4 Analysis by Leading Players
- 16.5 Analysis by Geography
- 17 Supplier Landscape
- 17.1 Market Share Analysis, By Region (Top 5 Companies)
- 17.1.1 Market Share Analysis: Global
- 17.1.2 Market Share Analysis: North America
- 17.1.3 Market Share Analysis: Europe
- 17.1.4 Market Share Analysis: Asia Pacific
- 17.1.5 Market Share Analysis: Others
- 17.2 Thermo Fisher Scientific Inc.
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Company News and Development
- 17.2.5 Certifications
- 17.3 Merck KGaA
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Company News and Development
- 17.3.5 Certifications
- 17.4 Danaher Corporation
- 17.4.1 Financial Analysis
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Company News and Development
- 17.4.5 Certifications
- 17.5 Becton, Dickinson and Company
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Company News and Development
- 17.5.5 Certifications
- 17.6 Terumo BCT, Inc.
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Company News and Development
- 17.6.5 Certifications
- 17.7 Novartis AG
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Company News and Development
- 17.7.5 Certifications
- 17.8 Sartorius AG
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Company News and Development
- 17.8.5 Certifications
- 17.9 Corning Incorporated
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Company News and Development
- 17.9.5 Certifications
- 17.10 Lonza
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Company News and Development
- 17.10.5 Certifications
- 18 Global Cell Therapy Market – Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.